4D Molecular Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
4D Molecular Therapeutics, Inc. (FDMT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $30.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-18
- 4D Molecular Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $30.50M, a 187.74% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $10.60M, a 70.64% decline from fiscal 2023.
- 4D Molecular Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $36.10M, a 15.71% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $31.20M, a 79.31% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $30.50M 10-K · filed 2026-03-18 |
| 2024-12-31 | $10.60M 10-K · filed 2026-03-18 |
| 2023-12-31 | $36.10M 10-K · filed 2025-02-28 |
| 2022-12-31 | $31.20M 10-K · filed 2024-02-29 |
| 2021-12-31 | $17.40M 10-K · filed 2023-03-15 |
| 2020-12-31 | $12.50M 10-K · filed 2022-03-28 |
| 2019-12-31 | $12.50M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |